Bullish Case: BRBR at $7.75 is down ~87% from two years ago yet Dymatize sales jumped 27% and forward P/E is ~5.9 vs 14.1 industry. Call volume runs 69% above puts (Nov $10 calls most active, delta 0.23), the Helium term structure sits in contango (Oct ~62-83% IV vs Dec ~103% upper band), and mean-reverting price action plus a historically fat right tail in the return surface suggest an oversold bounce toward $9-11 if litigation headlines stay dormant.

Bearish Case: Three separate law-firm investigations (Rosen, Halper Sadeh, KSF) plus an ongoing securities class action signal entrenched legal overhang. Price broke $13.86 (90-day) and $10.77 (30-day) with no stabilization; the Nov 21 IV peak (~112% upper band) implies the market prices event risk into the Nov 21/Dec 19 window. Nov $5 puts at 95.7 IV and deep-strike put skew show hedged, distributional demand. Prior bullish calls (rebound to $16-18) failed twice; momentum is firmly down.

Potential Outcomes:

1. 35%: Continued drift to $5.50-7.00 by Jan 2027 as litigation news and FY26 guidance cuts compound; IV stays >80%.
2. 30%: Baseline chop $7-9.50; contango persists, no new catalyst, IV slowly decays into Feb expiries.
3. 25%: Oversold rebound to $9-11.50 on short covering, Dymatize momentum, or litigation dismissal; front IV compresses.
4. 10%: Tail event (settlement, delisting risk, guidance withdrawal) drives sub-$5; Dec/Jan skew blows out.

Probabilities are scenario weights calibrated to the term structure and failed prior rebound calls.

September 30, 2026